Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of Liver

Cited by (418)

Items 301–400 of 418

1. Optimization of Tambjamines Active against Multiple Stages of Malaria Parasites
   Amrendra Kumar, Yue-Xin Li, Xiaowei Zhang, Xian-Nu Jin, William E Dennis, Ravi Chetree, Cameron Blount, Diana Caridha, Michael S Madejczyk, Patricia J. Lee et al. · 2025 · Journal of Medicinal Chemistry
2. PBPK models of the female reproductive tract: current and future analysis
   Kimberly A. Adams, Xinnong Li, Lisa Cencia Rohan, Robert R. Bies · 2025 · Expert Opinion on Drug Metabolism & Toxicology
3. PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?
   Justine Henriot, André Dallmann, François Dupuis, Jérémy Perrier, Sebastian Frechen · 2024 · CPT Pharmacometrics & Systems Pharmacology
4. The Effect of Malaria-Induced Alteration of Metabolism on Piperaquine Disposition in Plasmodium yoelii-Infected mice, as Well as Predicted in Malaria Patients.
   Yuewu Xie, Yifan Zhang, Feifei Lin, Xiaoyue Chen, Jie Xing · 2024 · International Journal of Antimicrobial Agents
5. Arsenic toxicokinetic modeling and risk analysis: Progress, needs and applications
   Elaina M. Kenyon · 2021 · Toxicology
6. Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.
   S. Degorce, A. Aagaard, R. Anjum, I. Cumming, C. Diène, C. Fallan, T. Johnson, Karl-Johan Leuchowius, A. L. Orton, S. Pearson et al. · 2020 · Bioorganic & Medicinal Chemistry
7. Further Assessment of the Relay Hepatocyte Assay for Determination of Intrinsic Clearance of Slowly Metabolised Compounds Using Radioactivity Monitoring and LC–MS Methods
   R. Murgasova · 2019 · European journal of drug metabolism and pharmacokinetics
8. Mechanistic Basis of Cabotegravir–Glucuronide Disposition in Humans
   Mitesh G. Patel, H. Eberl, Andrea Wolf, E. Pierre, J. Polli, M. Zamek-Gliszczynski · 2019 · Journal of Pharmacology and Experimental Therapeutics
9. Theoretical consideration of the properties of intestinal flow models on route‐dependent drug removal: Segregated Flow (SFM) vs. Traditional (TM)
   Keumhan Noh, K. Sandy Pang · 2019 · Biopharmaceutics & Drug Disposition
10. In Vitro Biotransformation in Drug Discovery
    Selvan Ravindran, Rutuja Rokade, J. Suthar, Pooja Singh, Pooja Deshpande, Rajeshree Khambadkar, Srushti Utekar · 2018 · Drug Discovery
11. Pradigastat disposition in humans:in vivoandin vitroinvestigations
    Alana L. Upthagrove, Jin Chen, Charles Daniel Meyers, Kenneth M. Kulmatycki, Angela Bretz, Lai Wang, Lana Peng, Safet Palamar, Melissa Lin, Tapan Majumdar et al. · 2016 · Xenobiotica
12. Study of the in vitro metabolism of TJ0711 using ultra high performance liquid chromatography with quadrupole time-of-flight and ultra fast liquid chromatography with quadrupole linear ion trap mass spectrometry.
    Lei Hu, Zhen-Hua Lv, Gao Li, Xiaolong Xu, Cheng-Hao Zhang, Peng Cao, Jiangeng Huang, Lu-Qin Si · 2015 · Journal of Separation Science
13. From in vitro hepatic metabolic studies towards human health risk assessment: Two case studies of diuron and carbosulfan
    Khaled Abass · 2013
14. Chapter 1. Human Biotransformation
    A. Parkinson, Brian W. Ogilvie, Brandy L. Paris, Tiffini Hensley, Greg J. Loewen · 2010
15. The Liver in Systemic Illness
    S. Beath · 2007
16. Mechanistic in vitro – in vivo extrapolation (IVIVE) approach using a biomimetic in vitro system for the prediction of hepatic clearance
    Seongwon Park, Sun-Sook Song, Woojin Jung, Hwi‐yeol Yun, Soyoung Lee, Sun‐Woong Kang, Jung‐woo Chae · 2025 · Computational and Structural Biotechnology Journal
17. Development of a PBPK Model for Lamotrigine which Incorporates Metabolism by UGT2B10: Impact of UGT2B10 Poor Metabolizer Phenotype and Pregnancy
    Iain Gardner, Aki T. Heikkinen, Lloyd Wei Tat Tang, K. Lapham, T. Goosen · 2025 · AAPS Journal
18. Hepatic and extra-hepatic metabolism of propylene glycol ethers in the context of central nervous system toxicity
    Sophie Werner, David Pamies, Marie‐Gabrielle Zurich, Laura Suter‐Dick · 2025 · Toxicology
19. Development, testing, parameterisation, and calibration of a human PBPK model for the plasticiser, di-(2-ethylhexyl) terephthalate (DEHTP) using in silico, in vitro and human biomonitoring data
    K. McNally, C. Sams, A. Hogg, George Loizou · 2023 · Frontiers in Pharmacology
20. Physiologically Based Pharmacokinetic Modelling and Simulation to Predict the Plasma Concentration Profile of Doxorubicin
    George A Mystridis, G. Batzias, I. Vizirianakis · 2022 · Pharmaceutics
21. Hepatic transporter‐mediated pharmacokinetic drug–drug interactions: Recent studies and regulatory recommendations
    Nihan Izat, Selma Şahin · 2021 · Biopharmaceutics & Drug Disposition
22. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties
    Jing-De Wu, Ying-Jie Cui, Yi-Gang Zhou, Long-Qian Tang, Cheng-Mei Zhang, Zhao-Peng Liu · 2019 · Investigational new drugs
23. The impact of variation in scaling factors on the estimation of internal dose metrics: a case study using bromodichloromethane (BDCM)
    E. Kenyon, Christopher R. Eklund, J. Lipscomb, R. A. Pegram · 2016 · Toxicology Mechanisms and Methods
24. Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity
    R. Thelingwani, Britta Bonn, K. Chibale, C. Masimirembwa · 2014 · Expert Opinion on Drug Metabolism & Toxicology
25. Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kinetics.
    M. Fransson, Jan Brugård, P. Aronsson, H. Gréen · 2012 · European Journal of Pharmaceutical Sciences
26. Deriving a Health-Based Guidance Value for 9,10-Anthraquinone via integrating PBTK modeling-based reverse dosimetry and In Vitro bioassays.
    Da Zhang, Miaoying Shi, Jun-Yu Ning, Shan Zheng, Yi Yang, Xu-Dong Jia, Yaru Tian, Zi-Nan Li, Nan Zhang, Ying Feng et al. · 2025 · Environment International
27. Scaling factors to inform in vitro-in vivo extrapolation from preclinical and livestock animals: state of the field and recommendations for development of missing data
    A. Zimmer, A. Collier · 2025 · Drug metabolism reviews (Softcover ed.)
28. Liver microsomal protein content and activity in patients with hepatocellular carcinoma and cirrhosis: implications for the in vivo prediction of individual hepatic clearance
    Jun Zhou, Na Gao, Xin Tian, Yan Fang, Jie Gao, Qiang Wen, Ming-Zhu Cui, Yun-fei Zhang, Sai-Fei Li, Lin-jing Jia et al. · 2025 · Journal of Gastrointestinal Oncology
29. Prediction of hepatic metabolic clearance in rats and dogs using long-term cocultured hepatocytes.
    Kenichi Umehara, Florian Klammers, Isabelle Walter, Tanvi Naik, Victor Dudal, Tobias Remus, Aynur Ekiciler, Isabelle Anderka, Alessandra Pugliano, Lena C. Preiss et al. · 2025 · Drug Metabolism And Disposition
30. From hazard to risk prioritization: a case study to predict drug-induced cholestasis using physiologically based kinetic modeling
    Véronique M P de Bruijn, Ivonne M.C.M. Rietjens · 2024 · Archives of Toxicology
31. Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data
    K. McNally, C. Sams, George Loizou · 2023 · Frontiers in Pharmacology
32. Establishing allometric relationships between microsomal protein and cytochrome P450 content with body weight in vertebrate species.
    L. Lautz, A. Hendriks, J. Dorne, J. Louisse, N. Kramer · 2023 · Toxicology
33. Stability investigations of cytochrome P450 (CYP) enzymes immediately after death in a pig model support the applicability of postmortem hepatic CYP quantification
    Kata W Pedersen, Jakob Hansen, J. Hasselstrøm, J. Jornil · 2021 · Pharmacology Research & Perspectives
34. LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay
    M. Attwa, A. Abdelhameed, Nasser S. Al-Shakliah, A. Kadi · 2020 · Drug Design, Development and Therapy
35. Comparison of in vivo derived and scaled in vitro metabolic rate constants for several volatile organic compounds (VOCs).
    E. Kenyon, Christopher R. Eklund, R. A. Pegram, J. Lipscomb · 2020 · Toxicology in Vitro
36. Simultaneous Assessment of Hepatic Transport and Metabolism Pathways with a Single Probe Using Individualized PBPK Modeling of 14CO2 Production Rate Data
    Yoko Franchetti, T. Nolin · 2019 · Journal of Pharmacology and Experimental Therapeutics
37. Modeling and Simulation of Triclosan Kinetics and Distribution in Humans Using PBPK Model
    V. Cascella, M. Andreassen, T. Husøy, H. Dirven, B. Lie · 2018 · Proceedings of The 59th Conference on imulation and Modelling (SIMS 59), 26-28 September 2018, Oslo Metropolitan University, Norway
38. Population‐Based Pharmacokinetic Modeling and Simulation
    Frédéric Y. Bois, Masoud Jamei · 2012 · Encyclopedia of Drug Metabolism and Interactions
39. Age‐Dependent Expression of Human Drug‐Metabolizing Enzymes
    R. Hines · 2012 · Encyclopedia of Drug Metabolism and Interactions
40. End-tidal Sevoflurane and Halothane Concentrations during Simulated Airway Occlusion in Healthy Humans
    N. Talbot, A. Farmery, K. Dorrington · 2009 · Anesthesiology
41. Determination of Intrinsic Clearance and Fraction Unbound in Human Liver Microsomes and In Vitro-In Vivo Extrapolation of Human Hepatic Clearance for Marketed Central Nervous System Drugs
    Veera Raghava Chowdary Palacharla, R. Nirogi, Nitesh Kumar, K. Nandakumar · 2024 · European journal of drug metabolism and pharmacokinetics
42. In Vitro Hepatic Metabolism Input Parameters Support Toxicokinetic Simulations for the Formation of Methoxy Propionic Acid From β‐Isomer Propylene Glycol Methyl Ether
    Sophie Werner, Lucie Hegg, N. B. Hopf, Myriam Borgatta, Laura Suter-Dick · 2024 · Pharmacology Research & Perspectives
43. A quest for the stereo-electronic requirements for selective agonism for the neurotrophin receptors TrkA and TrkB in 17-spirocyclic-dehydroepiandrosterone derivatives
    D. Narducci, Despoina Charou, Thanasis Rogdakis, Ioanna Zota, Vivi Bafiti, Maria Zervou, T. Katsila, A. Gravanis, Kyriakos C. Prousis, I. Charalampopoulos et al. · 2023 · Frontiers in Molecular Neuroscience
44. A Multidisciplinary Team-Based Classroom Exercise for Small Molecule Drug Discovery
    Charlotte A. Dodson, Stephen E. Flower, MARK P. THOMAS · 2023 · Journal of Chemical Education
45. Refinement and calibration of a human PBPK model for the plasticiser, Di-(2-propylheptyl) phthalate (DPHP) using in silico, in vitro and human biomonitoring data
    K. McNally, George Loizou · 2023 · Frontiers in Pharmacology
46. Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout
    M. Yamane, Fumihiko Igarashi, Tsuyoshi Yamauchi, T. Nakagawa · 2020 · Xenobiotica; the fate of foreign compounds in biological systems
47. The effects of aging on hepatic microsomal scaling factor and hepatocellularity number in the horse
    Khaled A. Shibany, S. Tötemeyer, S. Pratt, S. Paine · 2018 · Xenobiotica; the fate of foreign compounds in biological systems
48. Characterisation of artemisinin–chloroquinoline hybrids for potential metabolic liabilities
    R. Thelingwani, Carina Leandersson, Britta Bonn, Peter J. Smith, K. Chibale, C. Masimirembwa · 2016 · Xenobiotica; the fate of foreign compounds in biological systems
49. In VitroandIn VivoModels of Drug Metabolism
    Michael Sinz · 2012 · Encyclopedia of Drug Metabolism and Interactions
50. Prediction of Drug Clearance from Enzyme and Transporter Kinetics
    Priyanka Kulkarni, Amir S. Youssef, Aneesh A. Argikar · 2021 · Methods in molecular biology
51. Application of Computational Methods for the Safety Assessment of Food Ingredients
    Patra Volarath, Yu Zang, Shruti V. Kabadi · 2019 · Challenges and advances in computational chemistry and physics
52. Hit Triage: Medicinal Chemistry Strategies to Improve the Odds of Success in Discovery
    K. Freeman-Cook, Daniel W. Kung · 2009 · Topics in medicinal chemistry
53. Optimization of Prodiginines as Single-Dose Curative Antimalarials
    Amrendra Kumar, Yue-Xin Li, Xiaowei Zhang, M. Gaddam, Diana Caridha, Michael S Madejczyk, Xian-Nu Jin, William E Dennis, Ravi Chetree, Cameron Blount et al. · 2025 · Journal of Medicinal Chemistry
54. Research on the content and activity of CYP450 enzymes in human liver
    Cunzhen Zhang, Yan Fang, Lin-Jing Jia, Hai–Ling Qiao · 2025 · Drug Metabolism Reviews
55. The quest to define cancer-specific systems parameters for personalized dosing in oncology
    Areti‐Maria Vasilogianni, Brahim Achour, Zubida M. Al‐Majdoub, Sheila Annie Peters, Jill Barber, Amin Rostami‐Hodjegan · 2025 · Expert Opinion on Drug Metabolism & Toxicology
56. Novel Epigallocatechin Gallate (EGCG) Analogs with Improved Biochemical Properties for Targeting Extracellular and Intracellular Staphylococcus aureus
    Riley J Grosso, V. Nguyen, Syed Kaleem Ahmed, Annie Wong-Beringer · 2024 · Applied microbiology
57. Ontogeny of Scaling Factors for Pediatric Physiologically Based Pharmacokinetic Modeling and Simulation: Cytosolic Protein Per Gram of Liver
    Stephani L. Stancil, R. Pearce, Vincent S. Staggs, J. Leeder · 2023 · Drug Metabolism And Disposition
58. Metabolic profiling and in vitro-in vivo extrapolation of furathiocarb in mammalian hepatic microsomes
    Khaled Abass, Petri Reponen, W. Alsanie, A. Rautio, O. Pelkonen · 2022 · Toxicology Reports
59. Metabolic Retroversion of Piperaquine (PQ) via Hepatic Cytochrome P450–Mediated N-Oxidation and Reduction: Not an Important Contributor to the Prolonged Elimination of PQ
    Yuewu Xie, Yunrui Zhang, Hui-Xiang Liu, J. Xing · 2021 · Drug Metabolism And Disposition
60. Tiered approaches for screening and prioritizing chemicals through integration of pharmacokinetics and exposure information with in vitro dose-response data
    Jeremy A. Leonard, Yu‐Mei Tan · 2019 · Computational Toxicology
61. In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes
    Matthew Y Bendikov, J. Miners, B. Simpson, D. Elliot, Susan J. Semple, D. Claudie, R. Mckinnon, E. M. Gillam, Matthew J. Sykes · 2017 · Xenobiotica; the fate of foreign compounds in biological systems
62. Effect of Age on The Hepatocellularity Number for Wistar rats
    Sarinj Fattah, Patrick Augustijns, Pieter Annaert · 2015 · Drug Metabolism and Disposition
63. Modeling and Simulation of Triclosan Kinetics and Distribution in Humans Using a PBPK Model
    Samee Maharjan, Roshan Sharma, T. Husøy, H. Dirven, M. Andreassen, B. Lie · 2015
64. Physiologically Based Pharmacokinetic Modelling in Drug Delivery
    Raj Kumar Singh Badhan · 2015
65. Modélisation de la toxicocinétique des isomères cis et trans de la perméthrine et de ses métabolites chez le rat et de leur métabolisme sur hépatocytes humains
    Marie-Émilie Willemin · 2014
66. Evaluating the Cost-Effectiveness of Pharmacogenomics in Clinical Practice
    F. Shabaruddin, K. Payne · 2014
67. Drug Metabolism and Pharmacokinetics in Drug Discovery
    Kimberley A. Lentz, Joseph J. Raybon, Michael Sinz · 2013 · Drug Discovery
68. Incorporating Human Dosimetry and Exposure Information with High–Throughput Screening Data in Chemical Toxicity Assessment
    Barbara A. Wetmore, Russell S. Thomas · 2013 · Wiley eBooks
69. In VitroLiver Systems to Study Induction/Inhibition: Prediction ofIn VivoMetabolism and Drug–Drug Interactions
    Hiroshi Komura, Masahiro Iwaki · 2012 · Wiley eBooks
70. An Introduction to Metabolic Reaction Phenotyping
    Carl D. Davis, A. David Rodrigues · 2008 · Wiley eBooks
71. Use of Cytochrome P450-Specific Parameters and Human Biomarker Data To Develop a Human Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Dermal Chlorpyrifos Exposure
    C. Ellison, J. Knaak, Robin Mcdougall, J. Olson · 2012
72. Drug–Drug Interactions: What Have We Learned and Where Are We Going?
    K. Pang, Raimund M. Peter, A. Rodrigues · 2010 · Springer eBooks
73. Best Practices in Physiologically Based Pharmacokinetic ( PBPK ) Modeling
    Marylore Chenel, André Dallmann, Ibrahim Ince, Michaela C. Meyer, Jan‐Frederik Schlender, Donato Teutonico, Erik Sjögren · 2026 · CPT Pharmacometrics & Systems Pharmacology
74. Human internal exposures to alternariol and its monomethyl ether are predicted below thresholds of in vitro toxicity by physiologically based kinetic modeling
    E. Borsos, B. Descamps, N. Hetzschold, Elisabeth Varga, D. Marko, Georg Aichinger · 2026 · bioRxiv
75. Physiologically based toxicokinetic-toxicodynamic (PBTK-TD) modeling of oral exposure to bongkrekic acid in rats.
    Xiafei Cao, Jian Xiao, Yan Lei, Yuxin Zhong, Ling Hu, Xu-Sheng Li, Mei-Dan Liang, Kaizhou Chen, Wei-Bin Bai · 2026 · Food and Chemical Toxicology
76. Introduction to Single-cell Physiologically-Based Pharmacokinetic (scPBPK) Models
    Anshul Saini, James M. Gallo · 2026 · bioRxiv
77. Beyond the Michaelis–Menten: Evaluation of a tQSSA‐Based IVIVE Approach for Predicting In Vivo Intrinsic Clearance From Hepatocyte Assays
    Ngoc-Anh Thi Vu, Yun-Min Song, Sang Kyum Kim, Hwi-yeol Yun, Soyoung Lee, Jae Kyoung Kim, Jung-woo Chae · 2025 · CPT: Pharmacometrics & Systems Pharmacology
78. In Vitro to In Vivo Scalars for Drug Clearance in Nonalcoholic Fatty Liver and Steatohepatitis
    Teresa Sierra, B. Achour · 2024 · Drug Metabolism And Disposition
79. Applicability of generic PBK modelling in chemical hazard assessment: A case study with IndusChemFate
    Styliani Fragki, Aldert H. Piersma, Joost Westerhout, Anne S. Kienhuis, Nynke I. Kramer, Marco J. Zeilmaker · 2022 · Regulatory Toxicology and Pharmacology
80. Improved predictability of hepatic clearance with optimal pH for acyl-glucuronidation in liver microsomes.
    T. Mizutare, S. Sanoh, T. Kanazu, S. Ohta, Yaichiro Kotake · 2022 · Journal of Pharmacy and Science
81. LC–MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation
    Mohamed W. Attwa, Ali S. Abdelhameed, Adnan A. Kadi · 2021 · Drug Design Development and Therapy
82. Pharmacokinetics and safety of rilpivirine in healthy Japanese subjects and exploration of ethnic sensitivity of rilpivirine pharmacokinetics with physiologically based pharmacokinetic model approach.
    Kentaro Ohta, Nobuko Matsushima, H. Tanii, H. Crauwels, Toshiyuki Kudo, Kiyomi Ito · 2021 · Drug Metabolism and Pharmacokinetics
83. Linking internal dosimetries of the propyl metabolic series in rats and humans using physiologically based pharmacokinetic (PBPK) modeling.
    J. Smith, Kimberly J. Tyrrell, Jeremy P. Smith, K. Weitz, W. Faber · 2020 · Regulatory toxicology and pharmacology : RTP
84. 3. Metabolism: Principle, Methods, and Applications
    Souzan B. Yanni · 2015
85. In Vitro Experimental Models for Studying Drug Biotransformation
    Tonika Bohnert, Lawrence L. Gan · 2013 · Handbook of Metabolic Pathways of Xenobiotics
86. In Vitro–In Vivo Correlations of Hepatic Drug Clearance
    R. Obach · 2012
87. Physiologically‐Based Pharmacokinetic Modeling of Populations
    S. Peters · 2012
88. Drug Metabolism Research as Integral Part of Drug Discovery and Development Processes
    W. Humphreys · 2011
89. Recent Developments in Physiologically Based Pharmacokinetic Modeling
    Vikash Sinha, Holly H. C. Kimko · 2010 · AAPS advances in the pharmaceutical sciences series
90. Physiologically-based pharmacokinetic model to predict pharmacokinetics of KY0467 in humans and guide dose selection in infants and children
    Pan-Pan Xie, Ya Yang, Xue-Mei He, Ming Yang, Zhi-Xin Chen, Xiao-Hong Weng, A. Shi · 2026 · Frontiers in Pharmacology
91. Current knowledge of xenobiotic metabolism in the skin, associated in vitro and in silico models and their application to Next Generation Risk Assessments
    N. Golbamaki, S. Grégoire, N. J. Hewitt, Daniela Lange, Ans Punt, S. Spriggs, S. Sepehri, Nadia Heramvand, A. Cuciureanu, D. Allen et al. · 2026 · NAM journal
92. In Vitro-In Vivo Extrapolation of Hepatic Clearance for GalNAc-siRNA Therapeutics Using Rat Liver Tritosomes
    Harvey Andersen, Alec Bell, Ryan Hill, Anthony Murphy, Michael Huskin, M. Mohutsky, Christopher M. Wiethoff · 2026 · Drug Metabolism And Disposition
93. Investigating the Effect of Glutathione-Mediated Metabolism of Organophosphate Pesticides on Rat and Human Toxicokinetics Using Physiologically Based Kinetic Modeling.
    Thijs M. J. A. Moerenhout, W. Bakker, Hans Bouwmeester, Nynke I. Kramer · 2026 · Food and Chemical Toxicology
94. Assessing in vitro long-term liver metabolism models to characterize intrinsic clearance determination in NGRAs
    Jaqueline Meinhardt, Abdulkarim Najjar, Nicola J. Hewitt, Andreas G. Schepky, Daniela Lange · 2026 · NAM journal.
95. Understanding Interindividual Variability in Biotransformation and Renal Clearance to Improve Personalized Toxicokinetic Modeling in Chemical Assessments
    An Tran, Yongcheng Li, Li Li · 2026 · Environmental Science & Technology
96. Tebapivat: Pharmacokinetic Properties in Preclinical Species and Pharmacodynamic Responses Associated With Pyruvate Kinase Activation in Wild‐Type Mice
    Chuck W. Locuson, Sébastien Ronseaux, Michael McVay · 2026 · Biopharmaceutics & Drug Disposition
97. Application of New Approach Methodologies to Improve Oral Biopharmaceutic Assessments
    Mauricio A. García, M. Cabrera-Pérez, Pablo González, Alexis Aceituno, D. Hachim · 2026 · Pharmaceutics
98. Evaluation of the disconnect between hepatocyte and microsomal intrinsic clearance at intracellular and extracellular pH.
    Christine K. Maurer, Zhizhou Fang, S. Harlfinger, Carl Petersson · 2026 · Drug Metabolism And Disposition
99. Metabolic Profiling of Sitravatinib in Rat and Human Liver Microsomes Using LC–MS/MS and LC–Orbitrap–HRMS
    Shan Xu, Ying-Xing Zhu, Wenxia Liu, Guang-Ren Bao, Lin-Fei Li · 2025 · Rapid Communications in Mass Spectrometry
100. Preclinical Assessment and Tissue Distribution of Vodobatinib, a Third Generation BCr-Abl 1 Inhibitor
     Sandeep Kaddare, Ram Murthi Bestha, Niranjan Veerla, Keerthana Madipelli, Ashok Zakkula, Sreekanth Dittakavi, Ramesh Mullangi · 2025 · Drug Research